Melanoma Trials Should Allow Intron A-Naïve Patients, Advisory Cmte. Says
Executive Summary
Enrollment in melanoma drug trials should not be restricted to patients who have failed interferon alfa therapy, FDA's Oncologic Drugs Advisory Committee concluded Feb. 27